Menu Search
Equities

United Therapeutics Corp

UTHR:DEU

United Therapeutics Corp

Actions
  • Price (EUR)250.10
  • Today's Change-1.00 / -0.40%
  • Shares traded6.00
  • 1 Year change+25.52%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

  • Revenue in USD (TTM)2.50bn
  • Net income in USD1.05bn
  • Incorporated1996
  • Employees1.17k
  • Location
    United Therapeutics Corp1000 SPRING STSILVER SPRING 20910United StatesUSA
  • Phone+1 (301) 608-9292
  • Fax+1 (301) 608-9291
  • Websitehttps://www.unither.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		UTHR:NSQ since
announced		Transaction
value
IVIVA Medical IncDeal completed31 Oct 202331 Oct 2023Deal completed24.31%50.00m
Miromatrix Medical IncDeal completed30 Oct 202330 Oct 2023Deal completed25.10%139.42m
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.